Emma Andrus, Associate Editor

Keep up with the latest headlines in dermatology from the past week, including anti-racism training for dermatology residents, the creation of artificial "smart skin," and more.

More than half of treatment responders maintained stable EASI ≤ 7, according to a poster from EADV.

A poster presented at EADV 2024 explored patient-reported outcomes from. the TRACE study for AD.

A review examined how vitiligo treatments aim to restore melanocyte function through grafting, phototherapy, immune regulation, antioxidants, and stem cell research.

Researchers found that MBEHQ treatment increased oxidative stress and proinflammatory cytokines IL-1β and IL-18 in patients with vitiligo.

Catch up on the latest news on vitiligo advancements in 2024.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Dermatology Times is looking back on the top stories in dermatology from the month of September.

Dermatology Times is recapping our top expert interviews from the month of September.

Keep up with the latest headlines in dermatology from the past week, including regulatory updates for bimekizumab and roflumilast, semaglutide and HS, and more.

Researchers reported reductions in draining tunnels and total lesion counts.

Kilian Eyerich, MD, PhD, shares insights into an EADV 2024 presentation on upadacitinib’s ability to achieve almost total skin clearance in the head and neck regions with minimal effect on quality of life.

In addition to decreases in BMI, researchers also reported fewer HS flare ups.

Researchers presented interim 3-year results from the European SERENA study.

A new analysis from phase 3 studies shows Rinvoq's effectiveness for moderate to severe AD with head and neck involvement.

Farberg discusses data recently published in Geriatrics demonstrating low rates of recurrence.

VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.

The FDA has set a PDUFA target action date of May 22, 2025.

Review cutaneous signs and symptoms of HAE that may enhance early diagnosis and treatment.

Bimzelx was also approved for non-radiographic axial spondyloarthritis and ankylosing spondylitis.

Keep up with the latest headlines in dermatology from the past week, including data on AI versus dermatology residents, permanent makeup and the risk of allergic contact dermatitis, and more.

Lim discusses support for underserved communities, including dermatology training for Pacific Island Nations.

Elyse Love, MD, discusses the role of the program in supporting students with skin conditions the financial support and empowerment necessary for academic success.

Data was published in the Journal of the American Board of Family Medicine.

The Adbry 300 mg/2 mL autoinjector reduces the number of self injections required for patients, who currently have a 150mg/1mL pre-filled syringe available.

The conference aimed at providing dermatology NPs and PAs clinicians with the latest updates in the specialty begins today in Nashville, Tennessee.

Keep up with the latest headlines in dermatology from the past week, including the use of AI in a dermatology clinic to enhance gun safety, decreased rates of melanoma in Swedish adults under 50, and more.

Ebglyss is now approved for children and adults aged 12 years and older.

Researchers authored a manuscript detailing considerations for GPP diagnosis, definitions, and management.

Researchers reported several factors and indicators that may predict early-stage systemic sclerosis among patients in Japan.